Contact CFFC

Feb

Clinical Trial Alert – February 2020

Cystic Fibrosis Foundation issued the following clinical trial alert in February.

February 25, 2020

Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa

Status: Enrolling

Description: This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.

Age: 18 Years and Older

Mutation: No Mutation Requirement

Fev1% Predicted: 40 to 90%

Number of Visits: 6

Length of Participation: 2 months

ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT04279769


Comments are closed.